We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$52.9M
Cap. Flow %
-1.07%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75.69%
2 Consumer Discretionary 10.87%
3 Miscellaneous 10.83%
4 Consumer Staples 0.74%
5 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORTX
101
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$7.92M 0.16%
180,386
– –
SANA icon
102
Sana Biotechnology
SANA
$943M
$7.86M 0.16%
400,000
– –
ARAV
103
DELISTED
Aravive, Inc. Common Stock
ARAV
$7.84M 0.16%
1,311,291
– –
IMCR icon
104
Immunocore
IMCR
$1.63B
$7.81M 0.16%
200,000
– –
OMEG
105
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.46M 0.15%
750,000
– –
DCPH
106
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.32M 0.15%
200,000
– –
RXRX icon
107
Recursion Pharmaceuticals
RXRX
$1.75B
$7.3M 0.15%
+200,000
New +$5.92M
OLMA icon
108
Olema Pharmaceuticals
OLMA
$883M
$7.29M 0.15%
260,500
– –
SYRE icon
109
Spyre Therapeutics
SYRE
$7.96B
$7.27M 0.15%
41,800
– –
ORIC icon
110
Oric Pharmaceuticals
ORIC
$1.27B
$7.08M 0.14%
400,000
+300,000
+300% +$6.57M
SPRO icon
111
Spero Therapeutics
SPRO
$65.8M
$6.98M 0.14%
500,000
– –
CFRX
112
DELISTED
ContraFect Corporation
CFRX
$6.6M 0.13%
18,750
– –
FUSN
113
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$6.06M 0.12%
750,000
+210,736
+39% +$1.81M
HOOK
114
DELISTED
HOOKIPA Pharma
HOOK
$5.49M 0.11%
59,962
– –
ALPN
115
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.34M 0.11%
593,030
– –
NEUE
116
DELISTED
NeueHealth
NEUE
$5.24M 0.11%
+3,819
New +$5.23M
CRDF icon
117
Cardiff Oncology
CRDF
$109M
$4.99M 0.1%
750,000
– –
SNTI icon
118
Senti Biosciences Holdings
SNTI
$9.65M
$4.97M 0.1%
+50,000
New +$4.99M
CYPH
119
Cypherpunk Technologies Inc
CYPH
$240M
$4.92M 0.1%
300,000
– –
ALDX icon
120
Aldeyra Therapeutics
ALDX
$83.3M
$4.89M 0.1%
+431,894
New +$5.19M
MCRB icon
121
Seres Therapeutics
MCRB
$46.9M
$4.77M 0.1%
10,000
– –
MREO
122
Mereo BioPharma
MREO
$45.1M
$4.75M 0.1%
1,500,000
– –
IMMP
123
Immutep
IMMP
$48.7M
$3.87M 0.08%
+1,000,000
New +$3.96M
KLDO
124
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$3.72M 0.08%
500,500
– –
CDAK
125
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$3.71M 0.08%
200,000
– –
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2021 filing shows 19 new, 18 increased, 16 reduced and 21 closed positions. Its largest new stake was Oatly Group: 75,000 shares worth $36.7M. The largest sale was BioNTech, an estimated $98.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.